B A S E C A R E

Our mission

Help more families have healthy babies

We expertise in the research and application of genetic technology in reproductive health. In particular, we aim to help patients struggling with infertility and those afflicted with inheritance disorders.

Our Vision

A global leading genetic technology company

To provide a comprehensive clinical solution for reproductive health.

Basecare is a leading provider of IVF clinical solutions in China, as well as a company listed in the main board of Hong Kong Stock Exchange (stock code: 2170HK). Our mission is to help more families have healthy babies through the development and clinical application of high-throughput sequencing technology. Our vision is becoming a global leading genetic technology company.

Basecare remains a tight adherence to the idea of "making compliant products" and upholds the industrialization road of R&D, registration and sales. Basecare has extended its reach beyond the preimplantation stage to the prenatal and postnatal stages, completing a test kit pipeline that covers the full reproductive cycle. Basecare’s preimplantation genetic testing for aneuploidies (PGT-A) is the only NMPA approved third-generation IVF genetic test kit. PGT-M for monogenic and PGT-SR for structural rearrangement kits are expected to obtain NMPA registration certificate in 2022 and 2024, respectively. Together with the PGT-A kit, it will form a complete test kit lineup in the PGT filed.

Basecare provides integrated innovation platform solutions from detection reagents and devices to embryo storage instruments. We aim to realize the fully automated and digitalized intelligent hardware upgrades in the field of assisted reproduction by building high-end equipment R&D and manufacturing center. The clinical high-throughput gene sequencers (DA500) and the ultra-low temperature storage device (BSG800A) will obtain the registration approval in 2022 and 2023, respectively.

Development history

We march forward together

From the company's start-up to the clinical application, and then to the approval of PGT-A products on the
market, the development path of the decade is full of hardships and sweat Water, but more full of passion
and hope. We thank you for all the support you generously gave us in the past decade.

The company was founded to build a big data biological information analysis platform, and began to provide scientific research services based on the next generation sequencing technology.

2010
March

The PGT-A kit officially obtained the world's first registration certificate of Class III medical devices, and the PGT-A officially entered the era of certification.

2020
March

Our clinical trial for PGT-A kit is the world’s largest clinical trial with the largest amount of data.

2019
November

Obtained the GMP workshop production qualification, has the large-scale medical equipment production capacity, lays the solid foundation for the industrialization.

2018
August

Participated in the development of PGT-A quality control evaluation guidelines, to fill the gap of China's third generation IVF quality control technical standards.

2017
October

Established productive & genetic clinical research center with Thermo fisher.

2016
September

Approval of national innovative medical devices, which raised the level of standardization of third generation IVF industry.

2015
April

Cooperated with Dana gene to complete the registration of second generation sequencer and NIP kit.

2014
May

Set up joint laboratory with Life science to develop the first NIPT detection kit based on second generation sequencer.

2013
June

The company was founded to build a big data biological information analysis platform, and began to provide scientific research services based on the next generation sequencing technology.

2010
March